Search
1. Gastro-Intestinal System

NICE CG184: Dyspepsia and gastro‑oesophageal reflux disease: Investigation and management of dyspepsia, symptoms suggestive of gastro‑oesophageal reflux disease, or both

NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people

NICE CG61:  Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care

Dicycloverine
BNF | BNFC | SPC

Tablets - 10mg 

Syrup - 10mg/5ml 

Hyoscine Butylbromide
BNF | BNFC | SPC

Tablets - 10mg 

Mebeverine
BNF | BNFC | SPC

Tablets - 135mg 

Peppermint Oil
BNF | BNFC | SPC

E/C Capsules - 0.2ml 

Simeticone Infant Colic Drops / Suspension
BNF | BNFC | SPC

Less suitable for prescribing (evidence of benefit in infantile colic uncertain)  

Ranitidine
BNF | BNFC | SPC

Tablets - 150mg, 300mg 

Oral Solution - 75mg/5ml 

Cimetidine
BNF | BNFC | SPC

Tabs - 200mg, 400mg, 800mg

Oral Solution - 200mg/5ml

For occasional use in urticaria - unlicensed indication

Tripotassium dicitratobismuthate
BNF | BNFC | SPC

Tablets - 120mg (De-Noltab)

Sucralfate
BNF | BNFC | SPC

Tablets - 1g 

Suspension - 1g/5ml 

Misoprostol
BNF | BNFC | SPC

Tablets - 200microgram 

Lansoprazole
BNF | BNFC | SPC

Capsules - 15mg, 30mg 

Orodispersible Tablets - 15mg, 30mg 

Omeprazole
BNF | BNFC | SPC

Capsules - 20mg 

Esomeprazole
BNF | BNFC | SPC

Tablets - 20mg, 40mg 

Gastrointestinal Consultant Initiation Only

Loperamide
BNF | BNFC | SPC

Capsules - 2mg 

Syrup - 1mg/5ml 

Use of loperamide should be avoided in diarrhoea of infective origin until the infecting organism is known. Inappropriate use, particularly in Clostridium difficile diarrhoea, may result in development of toxic megacolon.

Balsalazide
BNF | BNFC | SPC

Capsules - 750mg 

Mesalazine
BNF | BNFC | SPC

Asacol

Tablets - 400mg, 800mg

Enema - 1g 

Suppositories - 500mg 

Pentasa

Tablets - 500mg 

Enema - 1g 

Suppositories - 1g 

Mezavant XL

Tablets - 1.2g 

The delivery mechanisms of oral mesalazine may vary. These preparations should not be considered interchangeable.

Sulfasalazine
BNF | BNFC | SPC

Tablets, EC Tablets - 500mg 

Suspension - 250mg/5ml 

Budesonide
BNF | BNFC | SPC

CR Capsules - 3mg 

2mg/metered application rectal foam

Hydrocortisone
BNF | BNFC | SPC

Foam - 10% 

Prednisolone
BNF | BNFC | SPC

Tablets - 1mg, 5mg 

EC Tablets - 5mg, 5mg 

Rectal Foam - 20mg 

Retention Enema - 20mg 

Suppositories - 5mg 

Bisacodyl
BNF | BNFC | SPC

EC Tablets - 5mg 

Suppositories - 5mg, 10mg 

Docusate Sodium
BNF | BNFC | SPC

Capsules - 100mg 

Oral Solution - 50mg/5ml, 12.5mg/5ml 

Micro-enema - 120mg in 10g 

Glycerol
BNF | BNFC | SPC

Suppositories  - 1g, 2g, 4g  

Arachis Oil
BNF | BNFC | SPC

Single Dose Enemas - 130ml 

Lactulose
BNF | BNFC | SPC

Solution

Hepatic encephalopathy and Paediatrics only. Initiated by a consultant

Macrogols
BNF | BNFC | SPC

Movicoloral Oral Powder

First line laxative for children

Naloxegol
BNF | BNFC | SPC

Film Coated Tablets - 12.5mg &  25mg 

Recommended by NICE for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives. An inadequate response is defined as opioid‑induced constipation symptoms of at least moderate severity in at least 1 of the 4 stool symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least 1 laxative class for at least 4 days during the prior 2 weeks

Prucalopride
BNF | BNFC | SPC

Tablets - 1mg, 2mg 

NICE TA211.

Recommended by NICE for treatment of chronic constipation in women for whom treatment with at least 2 laxatives from different classes, at highest tolerated recommended doses for at least 6 months, has failed and invasive treatment is being considered. Initiated only by clinicians experienced in treatment of chronic constipation. Should be reviewed if not effective after 4 weeks.

Lubiprostone
BNF | BNFC | SPC

Capsules - 24microgram 

Recommended by NICE for treatment of chronic constipation in Adults for whom treatment with at least 2 laxatives from different classes, at highest tolerated recommended doses for at least 6 months, has failed and invasive treatment is being considered. Initiated only by clinicians experienced in treatment of chronic constipation. Should be reviewed if not effective after 2 weeks.

Anusol HC
BNF | BNFC | SPC

Ointment

Suppositories

Proctosedyl
BNF | BNFC | SPC

Ointment  

Glyceryl Trinitrate
BNF | BNFC | SPC

Ointment - 0.4%  

NICE evidence summary for unlicensed / off-label medicines:

ESUOM7 Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment

Diltiazem cream
BNF | BNFC | SPC

Cream - 2% 

Initiation by specialist only (2nd line)

NICE evidence summary for unlicensed / off-label medicines:

ESUOM3: Chronic anal fissure: 2% topical diltiazem hydrochloride

Orlistat capsules
BNF | BNFC | SPC

Capsules - 60mg, 120mg  

 

Adjunct in obesity (in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m2 or more or in individuals with a BMI of 28 kg/m2 or more in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia)